Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Salute e medicinaOne-Off3a
Manifold MarketsSenza KYCDati di risoluzione verificatiBen calibratoPrevisione della comunità attualeSì 78.9%
Previsori
29
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 1 ora fa
In ritardo26 gen 24, 00:13 UTC1 gen 30, 07:59 UTC
Trend
Regole
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy.
- Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
- To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein).
- The gene therapy must be for humans.
- Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
